Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

August 25, 2015 | HCV, Latin America, hepatitis C 

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.

If left untreated, hepatitis C leads to chronic health problems putting a huge strain on national healthcare resources.

During the course of my working life, hepatitis C is one of the therapy areas in which I have seen the most dramatic advances in terms of treatment.  It is definitely one of pharma’s success stories. It has experienced rapid evolution from interferon- and ribavirin-based treatment in 1998, through pegylated interferon-based regimens and protease inhibitors and on to the recent wave of direct-acting antiviral therapies available today. It would not be an exaggeration to say that these interferon-free treatment regimens, with high efficacy (Sustained Virological Response (SVR) rates approaching 100%), minimal side effects and short treatment durations, have the potential to revolutionize the treatment of hepatitis C.

This article considers a more complex reality; how the availability of such exciting new treatments does not necessarily result in a treatment “revolution” in many emerging markets. Specifically, I will explore this in the context of the interesting example of Latin America. 

Read the full article http://www.researchpartnership.com/news/2015/06/breaking-down-the-barriers-to-effective-treatment-of…

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding

Webinar: Mobile Research in Asia and Emerging Markets

Current statistics around mobile technology reveal that many physicians in Asia are now using smartphones, tablets and other mobile devices to assist them in their daily practices. In China alone,73%...

Webinar: Understanding the Patient Journey in Order to Influence Prescribing Decisions

Using real data, this webinar looks at the increasingly popular view that says we need to understand more about the patient and the relationship they have with their physicians in...

Webinar: Focus on China: Conducting Research in the World’s Fastest Growing Pharma Market

This webinar looks to provide market research professionals with an overview of the Chinese healthcare market and provide participants with top tips for conducting relevant and effective market research in...

Webinar: Prescription Rationale: Physician Research via an iPhone App

This webinar explores the potential of using smartphone Apps as a platform for collecting detailed qualitative insights into physicians' decision rationale at the moment of prescription.

Maximising patient adherence by leveraging the patient/ physician/ pharma relationship

Director Marc Yates looks at the problem of patient compliance - can a better understanding of patient attitudes, needs and behaviours help pharma develop strategies to improve adherence?

Digital research in Asia

Director Marc Yates uses findings from a study conducted in six markets in Asia to explore how digital channels are being utilised by consumers and look at the digital opportunities...

Achieving customer centricity – Using immersion techniques to get closer to the pulse of the customer

Director Marc Yates discusses the importance of being customer-centric in the pharmaceutical industry and how immersion techniques in market research can help develop a better understanding of the customer.

The Mobile Revolution – Using mobile Apps to deliver “in-the-moment” market research to global healthcare

Director John Branston investigates the use of mobile research in order to capture immediate detailed, qualitative insights into prescription rationale at the patient level.